Related references
Note: Only part of the references are listed.Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Ammar Majeed et al.
CIRCULATION (2013)
Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis
J. -C. Lega et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Diagnostic management of acute deep vein thrombosis and pulmonary embolism
M. V. Huisman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Brian Dale et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?
William M. O'Neil et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis
Lana A. Castellucci et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran
Jeffrey I. Weitz et al.
CIRCULATION (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials
Benjamin D. Fox et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism
Marc Carrier et al.
ANNALS OF INTERNAL MEDICINE (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New oral anticoagulant drugs in cardiovascular disease
Ingo Ahrens et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme
Sylvia Haas
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
H. Buller et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) - The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study
Giancarlo Agnelli et al.
CIRCULATION (2007)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis -: A randomized trial
JN Fiessinger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis
LA Linkins et al.
ANNALS OF INTERNAL MEDICINE (2003)
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran
S Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
H Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis
K Wåhlander et al.
THROMBOSIS RESEARCH (2002)
Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy
JD Douketis et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
